- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03187444
Cardiovascular Risk and Chronic Inflammatory Rheumatism (RCVRIC)
Study Overview
Status
Intervention / Treatment
Detailed Description
All patients over 18 years, with rheumatoid arthritis treated for the first time with conventional anti-TNF therapy, Abatacept, Tocilizumab, Rituximab or patients with spondyloarthritis treated for the first time with NSAIDs that may be associated with conventional background treatments for peripheral or biological (anti-TNF, Usketinumab) may be included. However, they must be subject to a Social Security scheme and will only be able to participate in the research if they give their consent in writing after receiving full information.
In addition to the usual visit and after verification of the criteria of inclusion and signature of consent, arterial stiffness and endothelial function measurement are performed at M0, M6, M12 and every year and also at each change of treatment, By measuring the pulse wave velocity and by determining the Alx by the SphygmoCor XCEL (AtCor Medical Pty Ltd, based in Australia (CE 0120). Cardiac Frequency at rest will be evaluated at M0, M6, M12, every year and also at each change of treatment, by the realization of an electrocardiogram. The intima-media thickness (EIM) of the carotid will be evaluated every 5 years According to the recommendation. EIM is a non-invasive ultrasound technique in which an ultrasound probe is placed opposite the right primitive carotid artery by convention. A measurement of endothelial function will be performed at M0, M6, M12 and then every year in patients
A study of regional myocardial function by high-resolution echocardiography-STI will be carried out at M0, M6, M12 and then every year in non-hypertensive patients, without diabetes, without a cardiovascular history.
A Serum / plasma / urine bank will be constituted at M0, M6, M12, every year and also at each change of treatment to determine the markers of cardiovascular risk. The plasma bank will be used for the determination of nitric oxide.
A study of the body composition dual-energy x-ray absorptiometry (DXA) and pQCT allowing to evaluate lean mass, fat mass and bone mineral mass will be carried out at M0, then every year and also at each change of treatment M6 assessment of lean mass and fat mass only). When DXA is examined, a lateral incidence measurement of the rachis will be performed to calculate an arterial calcification score.
Muscle strength will be measured by hydraulic hand dynamometer Jamar (Kinetec company) at M0, M6, M12 then every year and also at each change of treatment. Physical performances will be evaluated by a 6-minute walking test, 10 meters walking speed and "Timed up-and-go test" stool test, which combines both coordination mechanisms, proprioception and muscular strength of lower limbs than M0, M6, M12 and then every year and also with each change of treatment.
The physical activity and physical inactivity of the patient and food habits will be assessed by the GPAQ (Global Physical Activity Questionnaire), FFQ and a Food questionnaire to M0, M6, M12 and every year and also to each change of treatment .
Depression will be assessed by the HAD self-administered questionnaire at M0, M6, M12 and then every year and also at each change of treatment.
Fibromyalgia will be assessed by the Fibromyalgia Rapid Screening Tool at M0, M6, M12 and then annually.
Comorbidities will be assessed by a nurse at M0, M12 and then annually.
All these examinations will be carried out in addition to the usual follow-up.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Auvergne
-
Clermont-Ferrand, Auvergne, France, 63003
- CHU de Clermont-Ferrand
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Being older than 18 years
- Have rheumatoid arthritis or spondyloarthritis (ankylosing spondylitis, psoriatic arthritis)
- Receive first conventional DMARD or biological treatment (anti-TNF, Abatacept, Tocilizumab, rituximab) for patients with rheumatoid arthritis
- Receive biological treatment (Abatacept, Tocilizumab, rituximab) for patients with rheumatoid arthritis who have failed anti-TNF treatment.
- Receive first NSAID (optionally combined with conventional DMARDs in case of peripheral arthritis) or biological treatment (anti-TNF, Usketinumab) for patients with spondyloarthritis.
- Being subject to a social security scheme
- Have the capacity to give informed consent and to comply with the study requirements
Exclusion Criteria:
- Patient refused to sign the consent form
- Patient under guardianship
- Patient having already been exposed to a biological as part of its pathology
- Patient with chronic disease may interfere with cardiovascular disease either by itself or by treatment history
- For echocardiography high resolution STI: Patients with hypertension, diabetes and cardiovascular history.
- To evaluate the activity of the autonomic nervous system, patients with hypertension, diabetics, with cardiovascular history with a neurological disease, with vasoactive or chronotropic treatments such as beta-blockers, antiarrhythmics, antihypertensives, anxiolytics, antidepressants
- Pregnant or lactating women will be temporarily excluded from the study during the period of pregnancy and breastfeeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patients with chronic inflammatory rheumatism
All patients over 18 years, with rheumatoid arthritis treated for the first time with conventional anti-TNF therapy, Abatacept, Tocilizumab, Rituximab or patients with spondyloarthritis treated for the first time with NSAIDs that may be associated with conventional background treatments for peripheral or biological (anti-TNF, Usketinumab) may be included.
|
Several examinations are realized on each patients, in addition to the usual visit and after verification of the criteria of inclusion and signature of consent.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline of the arterial Stiffness
Time Frame: at 6 months, 12 months
|
evaluated by the pulse wave velocity
|
at 6 months, 12 months
|
Change from baseline of resting heart rate
Time Frame: at 6 months, 12 months
|
at 6 months, 12 months
|
|
Change from baseline of endothelial function
Time Frame: at 6 months, 12 months
|
by Tonometry
|
at 6 months, 12 months
|
Change from baseline of intima-media thickness and carotid and femoral atheroma
Time Frame: at 5 years
|
at 5 years
|
|
Change from baseline of autonomic nervous system activity
Time Frame: at 6 months, 12 months
|
at 6 months, 12 months
|
|
Change from baseline of regional myocardial function
Time Frame: at 6 months, 12 months
|
at 6 months, 12 months
|
|
Change from baseline of other markers of cardiovascular risk
Time Frame: at 6 months, 12 months
|
troponin, NT_proBNP, adipocytokines, MCP-1, assymetric dimethylaarginine, angiopoietin-2, anti apo A-1, IL-6, IL-17
|
at 6 months, 12 months
|
Change from baseline of an abdominal aortic calcification score (DEXA)
Time Frame: at 6 months, 12 months
|
at 6 months, 12 months
|
|
Change from baseline of hand muscle strength (Handgrip)
Time Frame: at 6 months, 12 months
|
at 6 months, 12 months
|
|
Change from baseline of energy expenditure and physical activity in usual living conditions
Time Frame: at 6 months, 12 months
|
by Android application on smartphone (eMeetingSearch)
|
at 6 months, 12 months
|
Change from baseline of food habits
Time Frame: at 6 months, 12 months
|
French FFQ questionnaire
|
at 6 months, 12 months
|
Change from baseline of body composition
Time Frame: at 6 months, 12 months
|
DEXA, pQCT
|
at 6 months, 12 months
|
Change from baseline of inflammatory rheumatism
Time Frame: at 6 months, 12 months
|
by the doctor in charge of the patient
|
at 6 months, 12 months
|
Change from baseline of depression (HAD)
Time Frame: at 6 months, 12 months
|
at 6 months, 12 months
|
|
Change from baseline of fibromyalgia (FIRST)
Time Frame: at 6 months, 12 months
|
at 6 months, 12 months
|
|
Change from baseline of the frequency of comorbidities during inflammatory rheumatism
Time Frame: at 6 months, 12 months
|
at 6 months, 12 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Martin SOUBRIER, PhD MD, CHU de Clermont-Ferrand
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Immune System Diseases
- Autoimmune Diseases
- Joint Diseases
- Musculoskeletal Diseases
- Connective Tissue Diseases
- Bacterial Infections
- Bacterial Infections and Mycoses
- Streptococcal Infections
- Gram-Positive Bacterial Infections
- Spinal Diseases
- Bone Diseases
- Bone Diseases, Infectious
- Cardiovascular Diseases
- Arthritis
- Arthritis, Rheumatoid
- Rheumatic Diseases
- Collagen Diseases
- Spondylitis
- Spondylarthritis
- Rheumatic Fever
Other Study ID Numbers
- CHU-337
- 2014-A01847-40 (Other Identifier: 2014-A01847-40)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Diseases
-
Medical College of WisconsinActive, not recruitingCardiovascular Diseases | Cardiovascular Risk Factor | Cardiovascular HealthUnited States
-
Hospital Mutua de TerrassaCompleted
-
Oregon Health and Science UniversityCompletedCardiovascular Disease | Cardiovascular Risk FactorsUnited States
-
Women's College HospitalUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Brigham... and other collaboratorsUnknownCARDIOVASCULAR DISEASESCanada, United States
-
Groupe Hospitalier Paris Saint JosephTerminatedCARDIOVASCULAR DISEASESFrance
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
VA Office of Research and DevelopmentNot yet recruitingCardiovascular DiseaseUnited States
-
Baptist Health South FloridaUniversity of California, Los Angeles; Quest Diagnostics-Nichols InsituteActive, not recruitingCardiovascular DiseaseUnited States
-
Laval UniversityActive, not recruitingCardiovascular DiseaseCanada
-
Penn State UniversityCalifornia Healthcare InstituteCompleted
Clinical Trials on Examinations
-
Centre Hospitalier St AnneUnknownPatients With Cognitive DisturbancesFrance
-
University Hospital, ToulouseNot yet recruitingAttention Deficit Disorder With Hyperactivity
-
Memorial Sloan Kettering Cancer CenterRecruiting
-
The First Affiliated Hospital of Zhengzhou UniversityCompleted
-
Burapha UniversityCompletedAtrial Fibrillation | Type 2 DiabetesThailand
-
Fondazione Policlinico Universitario Agostino Gemelli...Recruiting
-
Oslo University HospitalRecruitingRetinitis Pigmentosa | Retinitis Pigmentosa 11Norway
-
University Hospital, LilleCompletedInflammatory Bowel DiseaseFrance
-
Cuiaba UniversityCompletedObesity | Diabetes | FastingBrazil
-
Peking University Third HospitalNot yet recruitingRotator Cuff Injury